Advances in breast cancer therapy mean that more women are surviving cancer but are at increased risk of cardiovascular disease (CVD). In a statement released by the AHA, Mehta and colleagues summarize the intersection between breast cancer and CVD, and highlight the importance of vigilance in preventive measures.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Moslehi, J. J. Cardiovascular toxic effects of targeted cancer therapies. N. Engl. J. Med. 375, 1457–1467 (2016).
Moslehi, J. The cardiovascular perils of cancer survivorship. N. Engl. J. Med. 368, 1055–1056 (2013).
Mehta, L. S. et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation 137, e30–e66 (2018).
Hortobagyi, G. N. et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N. Engl. J. Med. 375, 1738–1748 (2016).
Montazeri, K. et al. ABCDE steps to prevent heart disease in breast cancer survivors. Circulation 130, e157–e159 (2014).
Denlinger, C. S. et al. Survivorship, version 2.2017, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 15, 1140–1163 (2017).
Danilo, C. & Frank, P. G. Cholesterol and breast cancer development. Curr. Opin. Pharmacol. 12, 677–682 (2012).
Kitahara, C. M. et al. Total cholesterol and cancer risk in a large prospective study in Korea. J. Clin. Oncol. 29, 1592–1598 (2011).
Nelson, E. R. et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342, 1094–1098 (2013).
Borgquist, S. et al. Cholesterol, cholesterol-lowering medication use, and breast cancer outcome in the BIG 1-98 study. J. Clin. Oncol. 35, 1179–1188 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.M. has been a consultant for Bristol-Myers Squibb, Daiichi Sankyo, Novartis, Pfizer, and Takeda. M.M. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Moey, M., Moslehi, J. Cardiovascular disease and breast cancer. Nat Rev Cardiol 15, 200–202 (2018). https://doi.org/10.1038/nrcardio.2018.21
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2018.21
